Ocular Competitors

Stocks . USA . 
Stock . Ocular Therapeutix
OCUL Stock  USD 9.95  0.33  3.21%   
Ocular Therapeutix competes with Uniqure NV, Galapagos, Structure Therapeutics, Edgewise Therapeutics, and Viridian Therapeutics; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Ocular Therapeutix competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Ocular Therapeutix to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Ocular Therapeutix Correlation with its peers.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.

Ocular Therapeutix vs Immunitybio Correlation

Very good diversification

The correlation between Ocular Therapeutix and IBRX is -0.37 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ocular Therapeutix and IBRX in the same portfolio, assuming nothing else is changed.

Moving against Ocular Stock

  0.56PG Procter GamblePairCorr
  0.52CVX Chevron Corp Earnings Call TomorrowPairCorr
  0.42NVDA NVIDIA Aggressive PushPairCorr
  0.42ABEV Ambev SA ADR Aggressive PushPairCorr
  0.41GE GE AerospacePairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ocular Therapeutix's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
5.149.9514.76
Details
Intrinsic
Valuation
LowRealHigh
4.849.6514.46
Details
Naive
Forecast
LowNextHigh
5.8110.6115.42
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
9.9011.3212.73
Details

Ocular Therapeutix Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ocular Therapeutix and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ocular and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ocular Therapeutix does not affect the price movement of the other competitor.

High positive correlations

COGT
+ 0.88
VRDN
LQDA
+ 0.87
EWTX
LQDA
+ 0.86
GPCR
GPCR
+ 0.84
GLPG
LQDA
+ 0.81
VRDN
VRDN
+ 0.8
EWTX
  

High negative correlations

VRDN
- 0.65
QURE
COGT
- 0.55
QURE
LQDA
- 0.51
QURE
GPCR
- 0.46
QURE
EWTX
- 0.43
QURE
RCUS
- 0.39
QURE

Risk-Adjusted Indicators

There is a big difference between Ocular Stock performing well and Ocular Therapeutix Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ocular Therapeutix's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
QURE  4.51 (1.34) 0.00 (1.53) 0.00 
 0.00 
 7.15 
(10.75)
 49.34 
GLPG  1.01  0.09  0.04  0.23  1.19 
(1.06)
 2.62 
(1.87)
 7.08 
GPCR  5.21  2.27  0.58 (1.24) 2.90 
(7.02)
 8.23 
(5.94)
 110.34 
EWTX  4.15  0.89  0.19  1.00  4.23 
(5.10)
 12.91 
(5.57)
 38.85 
VRDN  1.93  0.59  0.36  1.79  1.15 
(2.53)
 5.57 
(2.19)
 15.86 
MESO  2.67  0.08  0.04  0.09  3.22 
(2.89)
 5.49 
(3.96)
 19.08 
COGT  4.89  1.89  0.65  0.57  2.27 
(7.11)
 5.51 
(4.44)
 126.24 
RCUS  2.65  0.24  0.04 (3.32) 4.33 
(2.61)
 5.64 
(6.53)
 19.63 
LQDA  2.96  0.98  0.26  2.71  3.02 
(3.34)
 8.00 
(4.45)
 19.63 
IBRX  5.26  1.74  0.35  2.48  4.26 
(6.91)
 11.16 
(7.49)
 51.87 

Ocular Therapeutix Competitive Analysis

The better you understand Ocular Therapeutix competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ocular Therapeutix's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ocular Therapeutix's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
OCUL QURE GLPG GPCR EWTX VRDN MESO COGT RCUS LQDA
 3.21 
 9.95 
Ocular
 2.78 
 23.66 
Uniqure
 0.09 
 34.13 
Galapagos
 2.13 
 87.15 
Structure
 0.35 
 28.78 
Edgewise
 0.15 
 33.57 
Viridian
 3.96 
 17.96 
Mesoblast
 1.85 
 37.65 
Cogent
 0.41 
 21.79 
Arcus
 2.74 
 43.06 
Liquidia
Market Volatility
(90 Days Market Risk)
Slightly risky
Somewhat reliable
Very steady
Somewhat reliable
Somewhat reliable
Very steady
Not too volatile
Somewhat reliable
Not too volatile
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Weakest
Fair
Good
Good
Solid
Soft
Fair
Soft
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Small
Small
Average
Low
Low
Small
Low
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Strong Hold
Strong Buy
Cautious Hold
Strong Buy
Strong Sell
Strong Hold
Current Ratio
6.14
10.84
8.23
N/A
27.49
7.77
1.9
11.96
6.22
13.81
Net Asset
457.94 M
556.54 M
4.14 B
903.33 M
486.82 M
742.4 M
784.68 M
327.9 M
1.15 B
230.31 M
Profit Margin
N/A
N/A
-1.52
N/A
N/A
N/A
N/A
N/A
-1.42
-1.79
EBITDA
(176.14 M)
(160.75 M)
43.33 M
(157.24 M)
(156.54 M)
(265.66 M)
(73.66 M)
(271.59 M)
(269 M)
(115.71 M)
Operating Margin
-4.72
-13.3
-0.59
N/A
N/A
-0.57
-3.02
N/A
-5.46
0.0325
Current Valuation
1.92 B
889.96 M
(1.35 B)
5.5 B
2.55 B
2.93 B
2.4 B
5.69 B
2.12 B
3.74 B
Price To Book
8.48
6.64
0.79
8.17
5.56
10.21
4.04
30.39
6.52
167.56
Retained Earnings
(891.08 M)
(1.13 B)
(134.31 M)
(329.1 M)
(378.58 M)
(995.86 M)
(1.01 B)
(859.48 M)
(1.13 B)
(559.49 M)
Current Asset
106.98 M
209.49 M
174.62 M
N/A
N/A
N/A
88.82 M
37.62 M
N/A
4.4 M
Beta
0.93
0.68
0.041
-2.15
0.27
0.95
0.76
0.51
0.78
0.49
Number Of Employees
274
209
704
218
136
143
81
205
627
170
Shares Outstanding
213.05 M
62.29 M
65.9 M
70.64 M
105.87 M
95.37 M
128.29 M
153.51 M
123.73 M
87 M
Cash Flow From Operations
(134.68 M)
(182.73 M)
(320.03 M)
(116.64 M)
(109.03 M)
(232.32 M)
(49.95 M)
(207.79 M)
(170 M)
(93.42 M)
Total Debt
75.78 M
66.06 M
11.72 M
3.86 M
4.74 M
21.09 M
128.16 M
17.47 M
60 M
122.39 M
Return On Equity
-0.82
-1.65
-0.17
-0.25
-0.3
-0.5
-0.19
-0.95
-0.68
-1.87
Return On Asset
-0.37
-0.14
-0.0519
-0.18
-0.21
-0.3
-0.0537
-0.47
-0.21
-0.25
Number Of Shares Shorted
12.79 M
11.57 M
928.02 K
6.25 M
9.42 M
8.15 M
2.64 M
16.44 M
8.9 M
12.69 M
Book Value Per Share
1.48
3.68
44.1
12.69
5.28
3.82
0.47
1.39
4.07
0.25
Current Liabilities
5.38 M
24.38 M
143.72 M
N/A
N/A
N/A
29.41 M
21.06 M
N/A
19.65 M
Total Asset
457.94 M
556.54 M
4.14 B
903.33 M
486.82 M
742.4 M
784.68 M
327.9 M
1.15 B
230.31 M
Debt To Equity
0.9
0.29
0.009
N/A
0.007
0.043
0.21
0.087
0.17
0.26
Short Ratio
2.92
4.7
11.18
5.08
6.06
5.23
10.06
5.92
4.84
7.22
Target Price
24.25
54.12
28.3
107.8
38.17
41.88
35.0
50.75
33.0
43.0
Shares Owned By Institutions
89.3
93.88
22.88
87.12
99.55
99.87
2.53
90.92
59.34
75.0
Market Capitalization
2.19 B
1.43 B
2.28 B
6.29 B
3.11 B
3.21 B
1.94 B
5.91 B
2.68 B
3.65 B
Price To Earning
-2.69
2.51
-15.6
N/A
3.45
N/A
-5.9
-5.03
27.69
-2.61
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.14
N/A
-0.04
Price To Sales
39.26
91.04
7.96
N/A
N/A
45.33
144.28
1320.63
11.19
52.68
Net Income
(193.51 M)
(239.56 M)
74.08 M
(122.53 M)
(133.81 M)
(269.95 M)
(102.14 M)
(255.86 M)
(283 M)
(130.39 M)
Earnings Per Share
-1.43
-4.4
-8.01
-3.66
-1.57
-3.03
-0.85
-2.05
-3.42
-1.46
Shares Owned By Insiders
2.81
5.33
25.35
2.51
0.45
0.13
5.0
0.28
30.01
13.43
Revenue
63.72 M
27.12 M
275.65 M
N/A
N/A
302 K
17.2 M
N/A
258 M
14 M
Working Capital
399.63 M
350.24 M
3 B
855.19 M
451.62 M
690.59 M
101.72 M
240.76 M
790 M
143.32 M
Cash And Equivalents
134.54 M
500.52 M
4.43 B
N/A
248.4 M
161.21 M
85.5 M
325.56 M
1.05 B
98.32 M
Cash Per Share
1.75
10.71
67.38
N/A
4.99
5.66
0.62
4.95
14.48
1.52
Gross Profit
(137.71 M)
(123.15 M)
(207.2 M)
N/A
N/A
(247.39 M)
(22.74 M)
(121.63 M)
(263 M)
61.67 M
Day Typical Price
10.17
23.38
34.14
87.55
28.83
33.59
18.04
37.82
21.77
42.9
Accumulation Distribution
295451.0
32263.91
664.06
27308.32
16037.34
30465.44
7967.88
27241.84
29994.19
240570.0
Daily Balance Of Power
(0.45)
0.6275
0.075
(0.58)
0.1087
(0.04)
(0.90)
(0.59)
0.1111
0.3979
Period Momentum Indicator
(0.33)
0.64
0.03
(1.90)
0.1
(0.05)
(0.74)
(0.71)
0.09
1.15
Rate Of Daily Change
0.97
1.03
1.0
0.98
1.0
1.0
0.96
0.98
1.0
1.03
Day Median Price
10.28
23.24
34.15
87.75
28.86
33.6
18.08
37.91
21.77
42.83
Price Action Indicator
(0.49)
0.74
(0.01)
(1.54)
(0.03)
(0.06)
(0.49)
(0.61)
0.07
0.81
Relative Strength Index
38.99
34.66
58.48
67.93
59.34
62.82
49.36
58.81
49.33
67.54
Coefficient Of Variation
(3,077)
(635.44)
1098.95
627.38
690.01
444.12
1886.93
744.62
1622.49
387.3
Mean Deviation
2.88
4.51
1.01
5.21
4.15
1.93
2.67
4.89
2.65
2.96
Jensen Alpha
(0.16)
(1.34)
0.09
2.27
0.8879
0.585
0.0782
1.89
0.2354
0.9835
Total Risk Alpha
(0.51)
(1.87)
0.0183
1.21
0.4746
0.4101
(0.07)
0.9797
(0.05)
0.7254
Sortino Ratio
N/A
N/A
0.0448
0.5788
0.1855
0.3612
0.036
0.6514
0.0383
0.2644
Downside Variance
N/A
N/A
2.11
13.47
22.73
2.33
10.89
9.69
22.17
12.94
Standard Deviation
4.81
8.15
1.39
13.71
6.53
2.72
3.4
15.55
3.92
3.92
Kurtosis
19.36
20.16
0.7371
49.61
4.77
5.87
1.16
55.72
3.29
1.17
Potential Upside
6.04
7.15
2.62
8.23
12.91
5.57
5.49
5.51
5.64
8.0
Treynor Ratio
0.9838
(1.53)
0.2254
(1.24)
1.0
1.79
0.0949
0.5656
(3.32)
2.71
Maximum Drawdown
35.7
49.34
7.08
110.34
38.85
15.86
19.08
126.24
19.63
19.63
Variance
23.09
66.35
1.93
188.04
42.59
7.39
11.57
241.91
15.39
15.38
Market Risk Adjusted Performance
0.9938
(1.52)
0.2354
(1.23)
1.01
1.8
0.1049
0.5756
(3.31)
2.72
Risk Adjusted Performance
(0.02)
(0.11)
0.0708
0.1252
0.1141
0.1708
0.0463
0.107
0.0529
0.1956
Skewness
3.51
(3.30)
0.3599
6.72
1.29
1.96
(0.08)
7.3
(1.14)
0.425
Semi Deviation
N/A
N/A
1.19
2.9
4.23
1.15
3.22
2.27
4.33
3.02
Information Ratio
(0.05)
(0.16)
0.0469
0.1549
0.1355
0.2026
0.035
0.1304
0.046
0.2426
Value At Risk
(5.06)
(10.75)
(1.87)
(5.94)
(5.57)
(2.19)
(3.96)
(4.44)
(6.53)
(4.45)
Expected Short fall
N/A
N/A
(1.06)
(7.02)
(5.10)
(2.53)
(2.89)
(7.11)
(2.61)
(3.34)
Downside Deviation
N/A
N/A
1.45
3.67
4.77
1.53
3.3
3.11
4.71
3.6
Semi Variance
N/A
N/A
1.42
8.42
17.91
1.32
10.35
5.15
18.76
9.11

Ocular Therapeutix Competition Performance Charts

Five steps to successful analysis of Ocular Therapeutix Competition

Ocular Therapeutix's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ocular Therapeutix in relation to its competition. Ocular Therapeutix's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Ocular Therapeutix in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ocular Therapeutix's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ocular Therapeutix, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Ocular Therapeutix position

In addition to having Ocular Therapeutix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cryptocurrency Thematic Idea Now

Cryptocurrency
Cryptocurrency Theme
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Ocular Therapeutix is a strong investment it is important to analyze Ocular Therapeutix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocular Therapeutix's future performance. For an informed investment choice regarding Ocular Stock, refer to the following important reports:
How To Invest In Ocular
Details
Is Ocular Stock a good investment?
Details
What is Ocular Therapeutix's Net Worth?
Details
Top Sectors
View
Check out Ocular Therapeutix Correlation with its peers.
For more information on how to buy Ocular Stock please use our How to buy in Ocular Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocular Therapeutix. Anticipated expansion of Ocular directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ocular Therapeutix assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Ocular Therapeutix's market price often diverges from its book value, the accounting figure shown on Ocular's balance sheet. Smart investors calculate Ocular Therapeutix's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Ocular Therapeutix's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Ocular Therapeutix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ocular Therapeutix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ocular Therapeutix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY